Last updated: February 13, 2026
What is the Current Market Status of NDC 00004-0350?
NDC 00004-0350 refers to Humira (adalimumab), a biologic used primarily to treat autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis. Humira remains the leading anti-TNF biologic globally, with significant sales volume despite increasing biosimilar competition.
The product is marketed by AbbVie and was initially approved by the FDA in December 2002. Humira maintained dominant market share in the biologic anti-TNF segment, but proliferation of biosimilars in the United States and Europe impacts its pricing, revenue, and market share.
As of 2022, the drug generated approximately $21.2 billion in global sales, sustaining its role as one of the best-selling pharmaceuticals [1].
How Has the Market for Humira Changed Recently?
Biosimilar Entry: Starting in 2023, multiple biosimilars entered the U.S. market, including Amgen’s Amjevita, Samsung’s Hadlima, and Pfizer’s Hyrimoz. These biosimilars are priced significantly lower—by 15-35%—than Humira’s original list price.
Market Share Shift: Post-biosimilar launch, Humira’s U.S. sales declined by approximately 23% in the first year, reflecting penetration of biosimilars and prescriber preference. On a global level, biosimilar adoption varies based on regulatory approval, reimbursement, and market dynamics.
Regulatory and Patent Landscape: Despite patent expirations, multiple legal challenges and patent extensions continue to delay full biosimilar market penetration in global markets. The U.S. patent cliff was reached in 2023, but some markets retain patent protections until 2025-2027.
Pricing Trends: List price reductions for Humira average around 20-25% in the U.S. after biosimilar launches. Net price declines are greater once rebates, discounts, and managed-care negotiations are accounted for.
What Are the Forecasts for Humira’s Pricing and Market Penetration?
Short-term projections (2023–2025):
- Biosimilar sales are expected to capture 35-50% of the anti-TNF market in the U.S.
- List prices are projected to decline by 20-30%, driven by biosimilar competition and payor discounts.
- Humira’s revenue in the U.S. could fall by 30-50%, depending on biosimilar market penetration.
Long-term outlook (2026–2030):
- The overall anti-TNF class will stabilize revenue streams with an estimated 10-15% CAGR decline in Humira’s U.S. sales through this period.
- Market share of biosimilars might reach 70-80% by 2028, further impacting Humira’s revenue.
- Global pricing will follow US trends but see slightly slower declines due to different regulatory and reimbursement environments.
Price Projections for Humira
| Year |
Estimated U.S. List Price per Syringe |
Projected U.S. Market Share |
Estimated Revenue Impact |
| 2023 |
$5,800 |
50% biosimilar market share |
$10.4 billion (~50% decline) |
| 2024 |
$5,600 |
60% biosimilar market share |
$8.4 billion (~60% decline) |
| 2025 |
$5,400 |
70% biosimilar market share |
$7.6 billion (~65% decline) |
| 2026 |
$5,200 |
80% biosimilar market share |
$6.4 billion (~70% decline) |
Note: These prices assume continued rebates and discounts typical in managed markets.
Strategic Implications
AbbVie has responded with pipeline diversification, including the development of Next-generation adalimumab and biosimilar coexistence strategies. Pricing and market share dynamics force new negotiation strategies with payors.
Investors should consider that patent protections expire soon and biosimilar competition will intensify, causing revenue and profit pressures. Negotiable discounts and the evolving landscape of biologic substitution policies impact future pricing.
Key Takeaways
- Humira remains the top-selling biologic but faces significant biosimilar competition in the U.S. and Europe.
- Presumed biosimilar market share could reach 70-80% by 2026, reducing revenue by up to 70%.
- Price declines are projected at 20-30% for list prices in the next two years.
- Long-term revenue decline is expected, with a compound annual rate of 10-15% post-2023.
- Strategic responses include pipeline expansion and biosimilar partnerships to offset revenue loss.
FAQs
1. How quickly will biosimilar market share grow in the U.S.?
Biosimilar adoption is expected to reach 50% by 2025, driven by improved formulary inclusion and increased prescriber acceptance.
2. What factors influence the pricing decline for Humira?
Market competition, patent expiry, rebate strategies, and payer negotiations primarily drive price reductions.
3. Are biosimilar savings consistent across countries?
No. Savings depend on local patent laws, regulatory approvals, and reimbursement policies, leading to variable biosimilar penetration globally.
4. Will AbbVie launch a new biologic to offset Humira loss?
AbbVie’s pipeline includes novel immunomodulators and biosimilars, aiming to diversify revenue streams and mitigate Humira’s decline.
5. What is the outlook for non-U.S. markets?
European markets, with later biosimilar entry, will experience slower declines initially. Emerging markets may see variable uptake based on local regulations and affordability.
Sources:
[1] IMS Health (IQVIA). "The Global Use of Medicine in 2022."
